Relmada Therapeutics (RLMD) Misses Q4 EPS by 10c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.27), $0.10 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Sandisk (SNDK) call put ratio 1 call to 1.2 puts a focus on June 26 weekly 1290 puts into Korean market weakness and Micron (MU) quarter results
• Netflix (NFLX) call put ratio 2.3 calls to 1 put